Cooperative Agreement R43CK000698

The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,857,470 Cooperative Agreement to The Geneva Foundation to develop a multiplex testing platform that can simultaneously detect and identify Plasmodium species infections. This platform will serve as both a diagnostic tool and an epidemiological surveillance tool. The project performance period is from June 1, 2024 to May 31, 2028. Under a $268,312 sub-award, Meso Scale...

This Cooperative Agreement award of $638,820 from the Defense Health Agency supports an mRNA multivalent approach to develop an innovative malaria vaccine. The project, funded through the Military Medical Research and Development program (CFDA 12.420), aims to broaden the immune targets against malaria infection by including both pre-erythrocytic-stage antigens and mosquito saliva antigens. The Geneva Foundation, a non-profit research organization, will conduct this research over a 3-year period...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

This $270,128 SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a low-cost, field-use DNA-based rapid diagnostic device for detecting plant diseases. The project aims to create a user-friendly, battery-operated testing kit that allows farmers to quickly identify diseases like citrus greening in their fields, enabling early intervention and more sustainable farming practices. The 9-month...

This $960,000 National Science Foundation project grant supports the development of a multiplexed plasmon-enhanced lateral flow assay for point-of-care detection of SARS-CoV-2 RNA and antigens. Funded under the NSF Engineering program (CFDA 47.041), the grantee, Washington University, will design, validate and build a novel diagnostic platform with sensitivity exceeding standard laboratory tests. Key deliverables include an ultrasensitive multiplexed lateral flow assay for simultaneous...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project grant, awarded to Anvil Diagnostics Inc. in the amount of $298,646, aims to develop a rapid diagnostic test for sepsis-causing pathogens in plasma samples using digital PCR hardware. The proposed technology seeks to comprehensively identify and quantify a panel of 17 common sepsis-causing pathogens within 4 hours from small blood volumes,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop new malaria vaccine candidates based on the Pf Glutamic Acid Rich Protein (PFGARP) antigen. The $412,500 award will be used by the University of South Florida to evaluate immunodominant fragments of PFGARP for potential inclusion in a malaria vaccine, with a focus on improving efficacy against the deadly Plasmodium...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Salus Discovery LLC for the development of a "FLOW DIRECT: NEXT GENERATION URINE LFA FOR TB DIAGNOSIS IN POINT-OF-CARE SETTINGS". This grant, awarded on July 10, 2024, will support Salus Discovery's research and development of an affordable, high-quality urine-based lateral flow assay (LFA) for the point-of-care...

This Cooperative Agreement, awarded by the Defense Health Agency, provides $568,275 in funding to Conserv Bioscience LIMITED, a foreign-owned for-profit organization, to develop an mRNA multivalent approach including pre-erythrocytic-stage antigens and mosquito saliva antigens to broaden the immune targets against malaria infection. The funding is provided through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical...

This National Science Foundation (NSF) Partnerships for Innovation - Research Partnerships (PFI-RP) project grant, CFDA #47.084, provides $549,649 to the University of Rochester to advance the development of a novel membrane-based sensor technology for the rapid and specific detection of infectious pathogens in biofluids. The project aims to integrate the membrane sensor into a hand-operated microfluidic device with a colorimetric readout, and demonstrate the generalizability of the approach...